Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe's only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility which offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development. Reliable laboratory analysis underpinned by scientific expertise is essential when processing and analysing clinical samples. Robust quality processes support our team of scientists in the delivery of submission ready data.
The Company has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. As announced in early March, Open Orphan is rapidly advancing a number of Coronavirus challenge study models and expects to be helping many COVID-19 vaccine development companies to test their vaccines. No other company in the world has such a portfolio, with only two competitors globally having 1 challenge study model each. In June 2020 hVIVO COVID Clear Test was launched, the most accurate antibody test available to UK employers, helping them to get their people back to work.
(Interview starts at 21 minutes 10 seconds)
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
(Sharecast News) - Stocks in London finished in the green on Monday, helped by the release of a much better than expected reading on euro area factory activity last month, and similarly upbeat survey results overnight in China.
Seeing Machines said total income, revenue and cash are ahead of market expectations for the period ended 30 June 2020. The driver monitoring system technology company said it continues to deliver its products across several industries despite the effects of the COVID-19 pandemic.
Union Jack Oil has a further 12.5% interest in PEDL180 and PEDL182 from Humber Oil & Gas, which the group says will have ‘an immediate positive by increasing its reserves and resources at Wressle by 45.5% to 1.24 million barrels of oil equivalent.
Versarien has today announced the launch of its first Graphene Enhanced Protective Face Mask, which utilises Polygrene, Versarien's graphene enhanced polymer to protect against airborne bacteria and minimise the spread of viral infection.
(Sharecast News) - Stocks in London are on the back foot at the start of August, weighed down by a retreat in lenders' shares and reports pointing to increasing odds that stricter Covid-19 restrictions were in the pipeline, both in the UK and the US.
New "life-saving" 90-minute tests which can detect coronavirus and flu will be rolled out in care homes and laboratories from next week. The "on-the-spot" swab and DNA tests will help distinguish between Covid-19 and other seasonal illnesses, the government said.